BEAM - BEAM

L'intérêt à découvert pour Beam Therapeutics donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Beam Therapeutics. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Beam Therapeutics (NASDAQ:BEAM) Stock, Rapport sur les intérêts à découvert

Beam Therapeutics

Beam Inc.

NYSE

Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.

Beam Therapeutics Inc

BEAM - United States Dollar

BEAM COMM HLDGS LTD by BEAM COMMUNICATIONS HLDGS LTD.

Beam Global

Beamr Imaging Ltd

BEAMZ INTERACTIVE INC by Beamz Interactive Inc

Beamz Interactive Inc

On Tuesday, Beam Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) announced that 35 patients have cleared screening and enrolled in the BEACON Phase 1/2 trial of BEAM-101, an investigational genetically modified cell therapy for <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41745039/beam-therapeutics-to-present-data-across-hematology-franchise-including-first-clinical-data-for-be" rel="noreferrer noopener">sickle cell disease (SCD)</a>.
Eight of these patients have been dosed with BEAM-101, while the other enrolled patients are going through pre-transplant stages, including cell collection and drug product manufacturing.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40375976/gene-editing-korro-bios-preclinical-data-best-in-class-analyst-initiates-with-outperform-rating" rel="noreferrer noopener">Gene Editing Korro Bio&#8217;s Preclinical Data &#8216;Best-In-Class&#8217;, Analyst Initiates With Outperform Rating</a>
In a company <a target="_blank" href="https://investors.beamtx.com/static-files/4e9eea51-c299-4b58-965a-87a5a8c3b62f" rel="noreferrer noopener">presentation</a>, preliminary safety data (N=6) showed an initial safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant (HSCT).
The company said that one patient died due to respiratory failure likely related to busulfan conditioning 4 months after BEAM-101 infusion. However, the investigator determined that the death was unrelated to BEAM-101.
The Data Safety Monitoring Committee and FDA reviewed the case.
In all patients dosed, there were no ≥ Grade 3 adverse events (AEs) or serious AEs related to BEAM-101.
Preliminary efficacy data showed that all patients achieved over 60% fetal hemoglobin (HbF, the main oxygen carrier protein in the human fetus) and less than 40% HbS (an abnormal type of hemoglobin that causes sickle cell disease) of non-transfused hemoglobin at Month 1, sustained through all time points.
Markers of hemolysis (destruction of red blood cells) normalized or improved for all patients.
No vaso-occlusive crises (VOCs, painful complication of sickle cell anemia) were reported by investigators following BEAM-101 treatment.
Beam Therapeutics said patient enrollment in the Phase 1/2 trial of BEAM-302 in patients with alpha-1 antitrypsin deficiency (AATD) is progressing. Site activation globally has continued, and dosing has been completed for the first cohort.
Beam has nominated a development candidate for its ESCAPE technology comprised of two investigational drug products: BEAM-103, an anti-CD117 monoclonal antibody (mAb), and BEAM-104, a cell therapy that includes the same therapeutic edit as BEAM-101 (editing the HBG1/2 genes to elevate fetal hemoglobin), plus an additional edit to CD117 which is designed to prevent binding of BEAM-103, allowing the edited cells to evade suppression by the antibody.
The company intends to advance BEAM-103 and BEAM-104 for development in SCD and beta-thalassemia.
Beam Therapeutics ended the third quarter of 2024 with $925.8 million in cash, cash equivalents, and marketable securities, providing a cash <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41739986/beam-therapeutics-reports-third-quarter-2024-financial-results-and-progress-across-priority-progra" rel="noreferrer noopener">runway into 2027</a>.
Price Action: BEAM stock is down 2.40% at $23.78&nbsp;at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41751557/nvidia-takes-short-lived-lead-over-apple-in-valuation" target="_blank" rel="noreferrer noopener">Nvidia Takes Short-Lived Lead Over Apple In Valuation</a></li>
</ul>

Biotech

News

Health Care

General

BEAM

Gene Therapy Developer Beam Therapeutics Reports One Patient Death In Early-Stage Sickle Cell Disease Trial

Highlights Also Include BEAM-201 CAR-T Therapy Data And Proof-Of-Concept For Non-Genotoxic Conditioning

Beam Therapeutics To Present Hematology Franchise Data At ASH Annual Meeting, Including First Clinical Data For BEAM-101 In Sickle Cell Disease And Preclinical ESCAPE Findings

WIIM

Beam Therapeutics shares are trading lower in reaction to a report indicating a patient in the company's CRISPR-based sickle cell treatment trial died.

<a href="https://www.statnews.com/2024/11/05/patient-dies-sickle-cell-beam-therapeutics-crispr/?utm_campaign=rss" title="https://www.statnews.com/2024/11/05/patient-dies-sickle-cell-beam-therapeutics-crispr/?utm_campaign=rss">https://www.statnews.com/2024/11/05/patient-dies-sickle-cell-beam-therapeutics-crispr/?utm_campaign=rss</a>

Patient In Beam Therapeutics' CRISPR Trial For Sickle Cell Disease Dies From Likely Chemotherapy Complications; Early Signs Of Gene Editing Effectiveness Observed In Other Participants

Earnings

Guidance

Beam Therapeutics Ended Third Quarter 2024 With $925.8M In Cash, Cash Equivalents and Marketable Securities; Expected Operating Runway into 2027

Beam Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) reported quarterly losses of $(1.77) per share which missed the analyst consensus estimate of $(1.19) by 48.74 percent. This is a 45.08 percent decrease over losses of $(1.22) per share from the same period last year. The company reported quarterly sales of $14.27 million which missed the analyst consensus estimate of $14.50 million by 1.58 percent. This is a 17.01 percent decrease over sales of $17.19 million the same period last year.

Beam Therapeutics Q3 2024 GAAP EPS $(1.77) Misses $(1.19) Estimate, Sales $14.27M Miss $14.50M Estimate

Beam Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) is set to give its latest quarterly earnings report on Tuesday, 2024-11-05. Here's what investors need to know before the announcement.
Analysts estimate that Beam Therapeutics will report an earnings per share (EPS) of $-1.16. 
The announcement from Beam Therapeutics is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Earnings Track Record</h3>
In the previous earnings release, the company beat EPS by $0.03, leading to a 4.15% drop in the share price the following trading session.
Here's a look at Beam Therapeutics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-1.14</td>
<td>-1.42</td>
<td>-1.01</td>
<td>-1.34</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-1.11</td>
<td>-1.21</td>
<td>1.73</td>
<td>-1.22</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-4.0%</td>
<td>-1.0%</td>
<td>-3.0%</td>
<td>-3.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1730736271_0.png" alt="eps graph" />
<h3>Beam Therapeutics Share Price Analysis</h3>
Shares of Beam Therapeutics were trading at $22.93 as of November 01. Over the last 52-week period, shares are down 5.08%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<h3>Analyst Observations about Beam Therapeutics</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Beam Therapeutics.
The consensus rating for Beam Therapeutics is Neutral, based on 7 analyst ratings. With an average one-year price target of $43.71, there's a potential 90.62% upside.
<h3>Comparing Ratings Among Industry Peers</h3>
In this comparison, we explore the analyst ratings and average 1-year price targets of and Mirum Pharmaceuticals, three prominent industry players, offering insights into their relative performance expectations and market positioning.
<h3>Analysis Summary for Peers</h3>
The peer analysis summary presents essential metrics for and Mirum Pharmaceuticals, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mirum Pharmaceuticals</td>
<td>Outperform</td>
<td>107.68%</td>
<td>$57.65M</td>
<td>-10.63%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Beam Therapeutics is positioned at the top for Revenue Growth among its peers, with a growth rate of 107.68%. However, it ranks at the bottom for Gross Profit margin, standing at -10.63%. In terms of Return on Equity, Beam Therapeutics is also at the bottom compared to its peers. Overall, Beam Therapeutics shows strong revenue growth but needs improvement in profitability and return on equity metrics.
<h3>All You Need to Know About Beam Therapeutics</h3>
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.
<h3>Unraveling the Financial Story of Beam Therapeutics</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Decline in Revenue: Over the 3 months period, Beam Therapeutics faced challenges, resulting in a decline of approximately -41.48% in revenue growth as of 30 June, 2024. This signifies a reduction in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Beam Therapeutics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -773.45%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Beam Therapeutics's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -10.3%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Beam Therapeutics's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -6.95%, the company may face hurdles in achieving optimal financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.19, Beam Therapeutics adopts a prudent financial strategy, indicating a balanced approach to debt management.
<a href="https://www.benzinga.com/quote/BEAM/earnings">To track all earnings releases for Beam Therapeutics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beam Therapeutics's Earnings: A Preview

Scotiabank analyst Greg Harrison initiates coverage on Beam Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) with a Sector Perform rating and announces Price Target of $24.

Price Target

Initiation

Analyst Ratings

Scotiabank Initiates Coverage On Beam Therapeutics with Sector Perform Rating, Announces Price Target of $24

RBC Capital analyst Luca Issi reiterates Beam Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) with a Sector Perform and maintains $27 price target.

Reiteration

RBC Capital Reiterates Sector Perform on Beam Therapeutics, Maintains $27 Price Target

Jones Trading analyst Soumit Roy initiates coverage on Beam Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) with a Hold rating.

Jones Trading Initiates Coverage On Beam Therapeutics with Hold Rating

In the latest quarter, 6 analysts provided ratings for Beam Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>), showcasing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $55.83, a high estimate of $80.00, and a low estimate of $27.00. This upward trend is evident, with the current average reflecting a 11.22% increase from the previous average price target of $50.20.
<img src="https://www.benzinga.com/files/images/story/2024/1726056040_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Beam Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benjamin Burnett</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$69.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$80.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Eric Joseph</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$48.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$31.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$27.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Announces</td>
<td>Buy</td>
<td>$80.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Beam Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Beam Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Beam Therapeutics's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Beam Therapeutics's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BEAM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Beam Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About Beam Therapeutics</h2>
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.
<h3>Breaking Down Beam Therapeutics's Financial Performance</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3 months period, Beam Therapeutics faced challenges, resulting in a decline of approximately -41.48% in revenue growth as of 30 June, 2024. This signifies a reduction in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Beam Therapeutics's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -773.45%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Beam Therapeutics's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -10.3%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Beam Therapeutics's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -6.95%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Beam Therapeutics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.19.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Beam Therapeutics Stock: Analyst Perspectives (6 Ratings)

Stifel analyst Benjamin Burnett maintains Beam Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) with a Buy and raises the price target from $66 to $69.

Stifel Maintains Buy on Beam Therapeutics, Raises Price Target to $69

5 analysts have shared their evaluations of Beam Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Beam Therapeutics, revealing an average target of $53.2, a high estimate of $80.00, and a low estimate of $27.00. Marking an increase of 15.03%, the current average surpasses the previous average price target of $46.25. 
<img src="https://www.benzinga.com/files/images/story/2024/1724331608_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
A clear picture of Beam Therapeutics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$80.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Eric Joseph</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$48.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$31.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$27.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Announces</td>
<td>Buy</td>
<td>$80.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Beam Therapeutics. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Beam Therapeutics compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Beam Therapeutics's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Beam Therapeutics's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/BEAM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Beam Therapeutics analyst ratings.</a>
<h2>Discovering Beam Therapeutics: A Closer Look</h2>
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.
<h3>Unraveling the Financial Story of Beam Therapeutics</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Beam Therapeutics's revenue growth over a period of 3 months has faced challenges. As of 30 June, 2024, the company experienced a revenue decline of approximately -41.48%. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Beam Therapeutics's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -773.45%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Beam Therapeutics's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -10.3%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -6.95%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.19.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Closer Look at 5 Analyst Recommendations For Beam Therapeutics

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Beam Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) with a Buy and maintains $80 price target.

HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target

William Blair initiated coverage on Korro Bio Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRRO#NASDAQ">KRRO</a>), a private RNA editing company that went public via a reverse merger with&nbsp;Frequency Therapeutics Inc. in an all-stock&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/23/07/33229914/why-are-frequency-therapeutics-shares-surging-today" rel="noreferrer noopener">merger transaction</a>.&nbsp;
The company&#8217;s proprietary Oligonucleotide Promoted Editing of RNA (OPERA) platform harnesses the body&#8217;s natural base editing system – specifically ADAR (Adenosine&nbsp;Deaminase&nbsp;Acting on&nbsp;RNA) – to make targeted edits to a single RNA base.
William Blair notes that ADAR editing permits chronic dosing and titratability of a genetic editing medicine without the risk of permanent off-target effects or potential issues with over- or underexpression of target genes.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/23/12/36075434/why-newly-listed-korro-bio-shares-are-gaining-today" rel="noreferrer noopener">Why Newly Listed Korro Bio Shares Are Gaining Today?</a>
William Blair emphasizes that Wave Life Sciences Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) is set to release the first clinical data for an ADAR-recruiting therapy in 2024. The analyst initiates <a target="_blank" href="https://www.benzinga.com/quote/KRRO/analyst-ratings" rel="noreferrer noopener">with an Outperform rating</a>.
The data from the Phase 1b/2a RestorAATion-2 trial of WVE-006 for severe Alpha-1 antitrypsin deficiency (A1ATD) will be crucial in determining whether the ADAR-mediated RNA editing mechanism is consistent across species—a key concern for investors due to differences in genetic homology.
Korro&#8217;s lead asset, KRRO-110, is a lipid nanoparticle (LNP)- encapsulated oligonucleotide designed to correct the E342K PiZ mutation in SERPINA1, which can lead to severe forms of alpha-1 antitrypsin deficiency (A1ATD).
The asset is expected to enter a Phase 1/2 trial in adult A1ATD patients in the second half of 2024, with interim proof-of-concept clinical data in 2025 and trial completion in 2026.
&#8220;We believe Korro&#8217;s preclinical data package, particularly in the NSG PiZ mouse model, is best-in-class for the ADAR field,&#8221; William Blair analyst writes.
&#8220;We also believe that Wave&#8217;s WVE-006 (GalNAc-conjugated ADAR-recruiting ASO) and Beam Therapeutics Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) BEAM-302 (base editing approach) clinical programs validate Korro&#8217;s approach but still leave clear room for differentiation on efficacy or specificity/safety,&#8221; the analyst adds.
Price Action: KRRO stock is up 8.64% at $39.50 at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/08/40373358/acelyrin-cuts-workforce-deprioritizes-former-lead-drug-izokibep" target="_blank" rel="noreferrer noopener">Acelyrin Cuts Workforce, Deprioritizes Former Lead Drug Izokibep</a>.</li>
</ul>
Don&#8217;t miss the opportunity to dominate in a volatile market at the <a href="https://www.benzinga.com/events/small-cap/global-small-cap-conference-2024/" target="_blank" rel="noreferrer noopener">Benzinga SmallCAP Conference</a> on Oct. 9-10 at the Chicago Marriott Downtown Magnificent Mile. Get exclusive access to CEO presentations, 1:1 meetings with investors, and valuable insights from top financial experts. Whether you&#8217;re a trader, entrepreneur, or investor, this event offers unparalleled opportunities to grow your portfolio and network with industry leaders. Secure your spot and get your tickets today!
Image via Shutterstock

Movers

KRRO

Gene Editing Korro Bio's Preclinical Data 'Best-In-Class', Analyst Initiates With Outperform Rating

JP Morgan analyst Eric Joseph maintains Beam Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) with a Overweight and raises the price target from $45 to $48.

JP Morgan Maintains Overweight on Beam Therapeutics, Raises Price Target to $48

Barclays analyst Gena Wang maintains Beam Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) with a Equal-Weight and lowers the price target from $33 to $31.

Barclays Maintains Equal-Weight on Beam Therapeutics, Lowers Price Target to $31

Beam Therapeutics Says Ended Q2 2024 With $1.0B In Cash, Cash Equivalents And Marketable Securities; Expected Operating Runway Into 2027

Beam Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) reported quarterly losses of $(1.11) per share which beat the analyst consensus estimate of $(1.25) by 11.2 percent. This is a 2.78 percent decrease over losses of $(1.08) per share from the same period last year. The company reported quarterly sales of $11.772 million which missed the analyst consensus estimate of $14.183 million by 17.00 percent. This is a 41.48 percent decrease over sales of $20.116 million the same period last year.

Earnings Beats

Earnings Misses

Beam Therapeutics Q2 2024 GAAP EPS $(1.11) Beats $(1.25) Estimate, Sales $11.772M Miss $14.183M Estimate

Beam Therapeutics GAAP EPS of -$1.17 misses by $0.02, revenue of $14.27M beats by $0.14M

BMO Capital says the first-ever clinical data from Beam Therapeutics (BEAM)' base editing platform in sickle cell disease, or SCD, demonstrate a "r...

Patient death post BEAM-101 doesn't seem related to Beam drug, says BMO

Beam Therapeutics (BEAM) is holding a conference call and audio webcast, during which it is discussing certain third quarter results of operations ...

Beam says patient death determined by investigator to be unrelated to BEAM-101

Beam Therapeutics (BEAM) announced the acceptance of multiple oral and poster presentations, including the first clinical data from a Beam program,...

Beam Therapeutics to present data on BEAM-101, BEAM-201 at ASH meeting

Beam Therapeutics ( ($BEAM) ) has issued an announcement. Beam Therapeutics is making strides in the field of genetic medicine with its innovative ...

Beam Therapeutics Advances in Genetic Medicine Innovations

William Blair analyst Sami Corwin has maintained their bullish stance on BEAM stock, giving a Buy rating today. Sami Corwin's rating is based on se...

Buy Rating Affirmed for Beam Therapeutics Due to Promising BEAM-101 Developments in Sickle Cell Disease Treatment

Beam Therapeutics Inc. (BEAM) Q3 2024 Earnings Call Transcript

Wedbush notes that in concurrent Q3 earnings and ASH abstract releases, Beam Therapeutics (BEAM) announced positive topline results for the Phase 1...

Beam could see significant upside over next 6-12 months, says Wedbush

In a report released today, Soumit Roy from JonesTrading reiterated a Hold rating on Beam Therapeutics (BEAM – Research Report). The company's shar...

JonesTrading Sticks to Their Hold Rating for Beam Therapeutics (BEAM)

20:38 EST Cathie Wood's ARK Investment buys 162.5K shares of Beam Therapeutics (BEAM) today Published first on TheFly – the ultimate source for rea...

Cathie Wood's ARK Investment buys 162.5K shares of Beam Therapeutics today

Press Releases

Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare Conference

Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid Congress

Beam Therapeutics to Participate in Jefferies Global Healthcare Conference

Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease

Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD)

Management

Beam Therapeutics Announces Transition of Chief Financial Officer

Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial Results

Beam Therapeutics to Hold Conference Call to Discuss Third Quarter 2024 Financial Results and Abstracts Accepted for Presentation at ASH Annual Meeting

Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs

Beam Therapeutics to Present Data Across Hematology Franchise, Including First Clinical Data for BEAM-101 in Sickle Cell Disease and ESCAPE Non-human Primate Data, at American Society of Hematology (ASH) Annual Meeting

Comments

Beam Therapeutics

Intérêt court

Beam Therapeutics (NASDAQ:BEAM) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL